General Archives - Page 90 of 2367

1 minute read

Why Is Marketing Solutions Provider Global-E Online’s Stock Surging Today?

May 20, 9:26 AM

Global-E Online shares surged after the company reported Q1 FY24 revenue of $145.90 million, beating estimates. Sales grew 24% Y/Y, while GMV increased 32% to $930 million. Non-GAAP gross profit rose 36% to $66.1 million. The company raised its FY24 sales forecast to $733 million - $773 million. CEO Amir Schlachet highlighted significant client additions and business expansion.

GLBE

2 minute read

Cannabis Rescheduling: When Will It Happen? Expert Lays Out Timeline, Risks And Wild Cards

By Nicolas Jose Rodriguez

May 20, 8:54 AM

The Department of Justice (DOJ) confirmed that it has started the formal rulemaking process to reclassify cannabis to Schedule III. This significant step reinforces the positive outlook for cannabis stocks.

ACB

1 minute read

GRI Bio Presents Preclinical Data Demonstrating GRI-0621 Reduces The Important Inflammatory And Fibrotic Drivers In Idiopathic Pulmonary Fibrosis

By Benzinga Newsdesk

May 20, 8:52 AM

Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung

GRI

1 minute read

CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine

By Benzinga Newsdesk

May 20, 8:42 AM

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron

ARCT

1 minute read

Johnson & Johnson Reports TREMFYA QUASAR Maintenance Study In UC Met Its Primary Endpoint And All Major Secondary Endpoints, Including Highly Statistically Significant Rates Of Endoscopic Remission

By Benzinga Newsdesk

May 20, 8:11 AM

Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative colitisa (UC)

JNJ

1 minute read

Ensysce Biosciences Renews Collaboration With Quotient Sciences To Undertake The Study PF614-MPAR-102 To Examine And Evaluate The Full Commercial Dose Range Of The PF614-MPAR Drug Product

By Benzinga Newsdesk

May 20, 8:07 AM

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPARSAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"),

ENSC

2 minute read

TikTok Parent ByteDance Overtakes Baidu In AI Chatbot Race In China: Report

By Shivani Kumaresan

May 20, 8:05 AM

ByteDance's AI chatbot, Doubao, has overtaken Baidu's Ernie Bot in both downloads and active users on iOS in China since its August launch. Doubao achieved nearly 9 million downloads and over 4 million monthly active users, while Ernie Bot garnered 8 million downloads.

AAPL

2 minute read

Why Is EHang Holdings Stock Rising Premarket Monday?

By Lekha Gupta

May 20, 7:17 AM

EHang Holdings reported 1Q FY24 results with revenue up 178%, positive operating cash flow, and projected 804% revenue increase for 2Q FY24.

2 minute read

Volkswagen’s Audi Partners With SAIC For New EV Platform In China

By Shivani Kumaresan

May 20, 6:42 AM

Audi, a subsidiary of Volkswagen AG, is developing new models on a China-specific "Advanced Digitized Platform" with SAIC. This collaboration will expand Audi's BEV portfolio in China, accelerating its transformation in the world's largest market. The first model is set to launch in 2025, reducing time-to-market by over 30%.

POAHF

1 minute read

Dyne Therapeutics Announced Clinical Data From Its Ongoing Phase 1/2 ACHIEVE Trial Of DYNE-101 In Myotonic Dystrophy Type 1 And Phase 1/2 DELIVER Trial Of DYNE-251 In Duchenne Muscular Dystrophy

By Benzinga Newsdesk

May 20, 6:33 AM

In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months DYNE-101 Showed Improvement in Myotonia, Muscle Strength, and Timed

DYN